JP5879036B2 - キナーゼ阻害剤としてのテトラヒドロシクロペンタ［ｃ］アクリジン誘導体およびその生物学的適用 - Google Patents

キナーゼ阻害剤としてのテトラヒドロシクロペンタ［ｃ］アクリジン誘導体およびその生物学的適用 Download PDF

Info

Publication number
JP5879036B2
JP5879036B2 JP2010542727A JP2010542727A JP5879036B2 JP 5879036 B2 JP5879036 B2 JP 5879036B2 JP 2010542727 A JP2010542727 A JP 2010542727A JP 2010542727 A JP2010542727 A JP 2010542727A JP 5879036 B2 JP5879036 B2 JP 5879036B2
Authority
JP
Japan
Prior art keywords
group
cyclopenta
tetrahydro
acridin
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010542727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509994A (ja
JP2011509994A5 (enExample
Inventor
フィリップ オリヴィエ ベルモント
フィリップ オリヴィエ ベルモント
ローラン マイヤー
ローラン マイヤー
フィリップ コーエン
フィリップ コーエン
アモリ パタン
アモリ パタン
ヨハン ボッソン
ヨハン ボッソン
ピーター グレゴリー ゲージアン
ピーター グレゴリー ゲージアン
Original Assignee
サーントゥル ナシオナル ドゥ ラルシェルシュ シャーンティフィク
サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーントゥル ナシオナル ドゥ ラルシェルシュ シャーンティフィク, サーントゥル ナシオナル ドゥ ラ ルシェルシュ シャーンティフィク filed Critical サーントゥル ナシオナル ドゥ ラルシェルシュ シャーンティフィク
Publication of JP2011509994A publication Critical patent/JP2011509994A/ja
Publication of JP2011509994A5 publication Critical patent/JP2011509994A5/ja
Application granted granted Critical
Publication of JP5879036B2 publication Critical patent/JP5879036B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2010542727A 2008-01-18 2009-01-19 キナーゼ阻害剤としてのテトラヒドロシクロペンタ［ｃ］アクリジン誘導体およびその生物学的適用 Expired - Fee Related JP5879036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0800275A FR2926550B1 (fr) 2008-01-18 2008-01-18 Derives de tetrahydrocyclopenta°c!acridines inhibiteurs de kinases et leurs applications biologiques
FR08/00275 2008-01-18
PCT/IB2009/050179 WO2009090623A1 (fr) 2008-01-18 2009-01-19 Dérivés de tétrahydrocyclopenta[c]acridines inhibiteurs de kinases et leurs applications biologiques

Publications (3)

Publication Number Publication Date
JP2011509994A JP2011509994A (ja) 2011-03-31
JP2011509994A5 JP2011509994A5 (enExample) 2012-03-01
JP5879036B2 true JP5879036B2 (ja) 2016-03-08

Family

ID=39477561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010542727A Expired - Fee Related JP5879036B2 (ja) 2008-01-18 2009-01-19 キナーゼ阻害剤としてのテトラヒドロシクロペンタ［ｃ］アクリジン誘導体およびその生物学的適用

Country Status (6)

Country Link
US (1) US8999955B2 (enExample)
EP (1) EP2244707A1 (enExample)
JP (1) JP5879036B2 (enExample)
CA (1) CA2711931A1 (enExample)
FR (1) FR2926550B1 (enExample)
WO (1) WO2009090623A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018135268A (ja) * 2015-06-05 2018-08-30 大日本住友製薬株式会社 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
CN105820119B (zh) * 2015-07-06 2019-04-02 盐城工学院 一种5，6-二氢苯并菲啶衍生物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569087A (da) * 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
CA2711931A1 (fr) 2009-07-23
US20100285124A1 (en) 2010-11-11
FR2926550A1 (fr) 2009-07-24
FR2926550B1 (fr) 2010-09-10
WO2009090623A1 (fr) 2009-07-23
EP2244707A1 (fr) 2010-11-03
JP2011509994A (ja) 2011-03-31
US8999955B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
JP7577069B2 (ja) 嚢胞性線維症膜貫通コンダクタンス制御因子調節剤
JP6770580B2 (ja) ピロロピリミジン５員環アザ環状誘導体およびその利用
JP7749263B2 (ja) Ｋａｔ６阻害剤としての化合物
JP2022529642A (ja) 二環式化合物
CN1910154B (zh) 用作分枝杆菌抑制剂的喹啉衍生物
WO2023280136A1 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP6250686B2 (ja) Ｒｏｒγｔのヘテロアリール結合させたキノリニルモジュレータ
HUP0301932A2 (hu) IL-1béta és TNF-a inhibitor benzofenon származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása gyógyszerkészítmények elżállítására
KR20100108337A (ko) 사람 면역결핍 바이러스 복제의 억제제
KR20190086442A (ko) 피리딘 화합물
HUP0103466A2 (hu) Foszfo-diészteráz-4 gátló hatású helyettesített 1,8-naftiridin-4(1H)-on származékok és ezeket tartalmazó gyógyszerkészítmények
CA3170503A1 (en) Stat degraders and uses thereof
JP4805166B2 (ja) アロイルフランおよびアロイルチオフェン
CN111630030A (zh) 作为PPAR-γ调节剂的新型苯甲酰胺衍生物
JP2016530304A (ja) チエノピペリジン誘導体およびその使用
EP2906539B1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN116406363A (zh) 四环类衍生物、其制备方法及其医药上的用途
JP5879036B2 (ja) キナーゼ阻害剤としてのテトラヒドロシクロペンタ［ｃ］アクリジン誘導体およびその生物学的適用
JP2009541470A (ja) 療法における２−ベンゾイル−イミダゾピリジンの使用
JP2023110094A (ja) Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
EP3668880B1 (en) Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
EP2080761A1 (en) Compounds
CN104610168A (zh) 巴比妥酸手性环己烷螺环化合物及其制备方法与用途
JP2011509251A (ja) Ｎ−フェニル−イミダゾ［１，２−ａ］ピリジン−２−カルボキサミド化合物、この調製およびこの治療的用途
CN120239694A (zh) 苯基氧基酰胺激酶抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150618

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160201

R150 Certificate of patent or registration of utility model

Ref document number: 5879036

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees